Abstract | BACKGROUND: AIM: METHODS: In this single-centre, double blind, double dummy study, patients with mild-to-moderate COPD ( GOLD stage II-III), were randomised to receive either placebo or two dosages of oral erdosteine (300 mg tid or 300 mg bid + 1 capsule of indistinguishable placebo) for 28 days in addition to their standard treatment. Primary variables were plasma reactive oxygen species (ROS) and 8-isoprostane levels, while secondary variable was lung function (FEV1; FEV1/FVC; FEV1 short-term reversibility), all assessed in baseline; every two weeks during the study, and one week after the end of the study. RESULTS: Baseline demographic characteristics, plasma ROS and 8-isoprostane levels and lung function were not significantly different in the 24 eligible patients (14 males, aged 38-75 years). At 2 weeks, there was a dose-dependent decrease in ROS in the erdosteine groups. By week 4 there were significant differences in ROS levels compared to baseline between patients receiving 900 mg/day (p < 0.003) and those receiving 600 mg/day (p < 0.04). This effect continued in the follow-up week (p < 0.021). Erdosteine also lowered 8-isoprostane plasma levels after 4 weeks (p < 0.01), and this effect lasted over the post-treatment week. Moreover, % FEV1 reversibility after salbutamol 400 mcg obtained after a 4 -week treatment of erdosteine 900 mg/day was significantly higher than that obtained after 600 mg/day (p < 0.01). Erdosteine was well tolerated and no treatment-related adverse event was reported. CONCLUSIONS: Results confirm the antioxidant dose- and time-dependent activity of erdosteine, and support the utility of including erdosteine it in the therapeutic strategy for the prevention and treatment of oxidative stress-induced inflammation, which frequently leads to AECOPD occurrence.
|
Authors | R W Dal Negro, M Visconti, P Turco |
Journal | Pulmonary pharmacology & therapeutics
(Pulm Pharmacol Ther)
Vol. 33
Pg. 47-51
(Aug 2015)
ISSN: 1522-9629 [Electronic] England |
PMID | 26116425
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)
|
Copyright | Copyright © 2015 Elsevier Ltd. All rights reserved. |
Chemical References |
- Antioxidants
- Bronchodilator Agents
- Expectorants
- Reactive Oxygen Species
- Thioglycolates
- Thiophenes
- erdosteine
- Albuterol
|
Topics |
- Administration, Oral
- Adult
- Aged
- Albuterol
(pharmacology)
- Antioxidants
(administration & dosage, pharmacology)
- Bronchodilator Agents
(pharmacology)
- Dose-Response Relationship, Drug
- Double-Blind Method
- Expectorants
(administration & dosage, pharmacology, therapeutic use)
- Female
- Follow-Up Studies
- Forced Expiratory Volume
(drug effects)
- Humans
- Inflammation
(drug therapy, physiopathology)
- Male
- Middle Aged
- Oxidative Stress
(drug effects)
- Pulmonary Disease, Chronic Obstructive
(drug therapy, physiopathology)
- Reactive Oxygen Species
(metabolism)
- Thioglycolates
(administration & dosage, pharmacology, therapeutic use)
- Thiophenes
(administration & dosage, pharmacology, therapeutic use)
|